Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
Dayal, Neetu
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. [electronic resource] - Future medicinal chemistry 04 2018 - 823-835 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1756-8927
10.4155/fmc-2017-0298 doi
Antineoplastic Agents--pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
G1 Phase--drug effects
Humans
Leukemia, Myeloid, Acute--drug therapy
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Mutation
Protein Kinase Inhibitors--pharmacology
fms-Like Tyrosine Kinase 3--antagonists & inhibitors
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. [electronic resource] - Future medicinal chemistry 04 2018 - 823-835 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1756-8927
10.4155/fmc-2017-0298 doi
Antineoplastic Agents--pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
G1 Phase--drug effects
Humans
Leukemia, Myeloid, Acute--drug therapy
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Mutation
Protein Kinase Inhibitors--pharmacology
fms-Like Tyrosine Kinase 3--antagonists & inhibitors